FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.
Lindsay Baker Kilburn,Nada Jabado,Andrea Franson, Susan N. Chi,Michael J. Fisher,Darren R. Hargrave,Jordan R. Hansford,David S. Ziegler,Daniel Landi,Hyoung Jin Kang,Nicolas U. Gerber,Michal Yalon-Oren,Izzy Cornelio,Samuel C. Blackman,Michael Craig Cox,Olaf Witt,Michael Prados,Sabine Mueller JOURNAL OF CLINICAL ONCOLOGY（2021）
AI 理解论文
溯源树
样例
